Anaphylaxis
is a severe, life‑threatening allergic reaction

Epinephrine (adrenaline)
is the only first-line, life-saving treatment

Millions Remain Without
Access to Treatment

40
MILLION
at-risk people
do not have access to
life‑saving epinephrine across
Europe and the U.S.1,2
1DuToit et al., (2024)., 2PharmaVentures Ltd (Unpublished Report). (2022)., 3Sheikh et al., (2015).
Barriers to Care Leave Too Many
Patients at Risk
1in2
patients
do not administer auto-injectors
even when a device is available1
86%
of all reactions
do not receive epinephrine before
emergency services arrive.2,3
1Sheikh et al., (2015)., 2PharmaVentures Ltd (Unpublished Report). (2022)., 3Miles et al., (2021).
Barriers to Care Reduce
Treatment Access
Marketed Epinephrine Products*Barrier to Care
Most patients rely on auto-injectors devices that deliver epinephrine using an injection
Patients may delay or avoid injections
due to fear of needles1,2
Currently approved devices deliver epinephrine using either injections or a nasal spray
May take 20-30 minutes to reach peak epinephrine absorption3,4
Currently approved devices recommend
everyday storage between 20 – 25°C5,6
Common storage locations may affect reliability and performance (car, handbag, etc.,)8-11
Most patients rely on auto-injector devices that expire 12 to 24 months after manufacture6,7
Frequently replacing devices can be
expensive and difficult to sustain12
*Current as of 16th July 2026., 1Brooks et al., (2017)., 2Alsbrooks & Hoerauf. (2022)., 3ARS Pharmaceuticals, Inc. (2023)., 4De Motu Cordis Pty. Ltd. (Unpublished Clinical Study Report). (2023)., 5ARS Pharmaceuticals, Inc. (Accessed 2026)., 6Mylan. (2020)., 7Australasian Society of Clinical Immunology and Allergy (ASCIA). (2026)., 8Rachid et al., (2015)., 9Warren et al., (2018)., 10Rachid et al., (2016)., 11Dadour et al., (2011)., 12Fineman et al., (2013).
Breaking Down Barriers to Care
De Motu Cordis is developing an inhalable epinephrine product to treat anaphylaxis that is designed to be simple, portable, and suitable for everyday storage, so it’s ready when you need it most.
Find out how De Motu Cordis aspires to change anaphylaxis treatment…





